PolyPid (Nasdaq:PYPD) - Stock Price, News & Analysis

PYPD Stock Overview

PolyPid Ltd., una empresa biofarmacéutica en fase clínica que desarrolla terapias dirigidas, administradas localmente y de liberación prolongada utilizando su tecnología patentada de matriz de encapsulación polimérica-lipídica (PLEX) para dar respuesta a necesidades médicas no cubiertas.

About the company

PYPD fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Los analistas coinciden en que el precio de las acciones subirá un 95.5%

Risk Analysis

Los accionistas se han diluido sustancialmente en el último año

Se prevé que los beneficios disminuyan una media de 4.3% al año durante los próximos 3 años.

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Fondos propios negativos

+ 3 more risks

PolyPid Ltd. Competitors

Cumberland Pharmaceuticals

NasdaqGS:CPIX

US$25.0m

TherapeuticsMD

NasdaqGS:TXMD

US$25.4m

Lipocine

NasdaqCM:LPCN

US$25.5m

Talphera

NasdaqGM:TLPH

US$20.4m

Price History & Performance

Summary of all time highs, changes and price drops for PolyPid
Historical stock prices
Current Share Price	US$4.50
52 Week High	US$14.10
52 Week Low	US$3.57
Beta	1.41
1 Month Change	-17.43%
3 Month Change	-34.69%
1 Year Change	-64.71%
3 Year Change	-98.39%
5 Year Change	n/a
Change since IPO	-99.21%

Recent updates

PolyPid set to cut 20% jobs

Oct 20

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

Sep 28

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

Sep 02

PolyPid GAAP EPS of -$1.23 misses by $0.60

Aug 10

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

Aug 03

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Mar 09

PolyPid's oncoplex cancer program shows encouraging action in animal study

Dec 22

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

Dec 16

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

Nov 24

Shareholder Returns

	PYPD	US Pharmaceuticals	US Market
7D	-8.0%	-1.2%	-0.7%
1Y	-64.7%	15.8%	25.9%

Rentabilidad frente al sector: PYPD obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del -3.7%.

Rentabilidad vs. Mercado: PYPD obtuvo unos resultados inferiores a los del mercado US, que fue del 14.1% el año pasado.

Price Volatility

Is PYPD's price volatile compared to industry and market?
PYPD volatility
PYPD Average Weekly Movement	13.4%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: PYPDha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: PYPD(17%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.

About the Company

Founded	Employees	CEO	Website
2008	61	Dikla Czaczkes Akselbrad	https://www.polypid.com

PolyPid Ltd. es una empresa biofarmacéutica en fase clínica que desarrolla productos terapéuticos específicos, de administración local y liberación prolongada mediante su tecnología patentada de matriz de encapsulación de polímeros y lípidos (PLEX) para satisfacer necesidades médicas no cubiertas. Su principal producto candidato es D-PLEX100, que se encuentra en un ensayo pivotal de confirmación de fase 3 para la prevención de infecciones del sitio quirúrgico (ISQ) en pacientes sometidos a cirugía colorrectal abdominal con grandes incisiones. También está desarrollando OncoPLEX, para el tratamiento del cáncer intratumoral.

PolyPid Ltd. Fundamentals Summary

How do PolyPid's earnings and revenue compare to its market cap?
PYPD fundamental statistics
Market cap	US$23.15m
Earnings (TTM)	-US$23.86m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Is PYPD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PYPD income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$23.87m
Earnings	-US$23.86m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.97
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-495.3%

How did PYPD perform over the long term?

See historical performance and comparison

PYPD Stock Overview

Rewards

Risk Analysis

PolyPid Ltd. Competitors

NasdaqGS:CPIX

US$25.0m

NasdaqGS:TXMD

US$25.4m

NasdaqCM:LPCN

US$25.5m

NasdaqGM:TLPH

US$20.4m

Price History & Performance

Recent News & Updates

PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial

PolyPid Ltd. to Report Q4, 2023 Results on Feb 14, 2024

PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.

PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors

Polypid Announces the Addition of Dr. Nurit Tweezer-Zaks to Its Board of Directors

PolyPid Ltd. to Report Q3, 2023 Results on Nov 08, 2023

Recent updates

PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial

PolyPid Ltd. to Report Q4, 2023 Results on Feb 14, 2024

PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.

PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors

Polypid Announces the Addition of Dr. Nurit Tweezer-Zaks to Its Board of Directors

PolyPid Ltd. to Report Q3, 2023 Results on Nov 08, 2023

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

PolyPid Announces Reverse Share Split to Regain Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement

PolyPid Ltd. Announces Successful Completion of Manufacturing Process Validation for D-PLEX100

PolyPid Ltd. to Report Q2, 2023 Results on Aug 09, 2023

Polypid Ltd. Announces New Publication Highlighting Potent Antibacterial Activity of D-Plex Against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

PolyPid Ltd. Announces Recruitment of First Patient in Revised Shield Ii Phase 3 Trial Evaluating D-Plex100 for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

PolyPid Ltd Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. Announces Board Changes

PolyPid Ltd. to Report Q4, 2022 Results on Feb 08, 2023

PolyPid Provides Positive Regulatory Update for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Polypid Ltd. Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-Hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

Price target decreased to US$3.38

PolyPid Ltd. to Report Q3, 2022 Results on Nov 09, 2022

PolyPid set to cut 20% jobs

Polypid Ltd. Announces Eligibility for European Medicines Agency Centralized Procedure for D-Plex100 for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX100 in the Prevention of Surgical Site Infections in Abdominal Surgery

Price target increased to US$24.33

PolyPid Ltd. Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

PolyPid GAAP EPS of -$1.23 misses by $0.60

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

PolyPid Ltd. to Report Q2, 2022 Results on Aug 10, 2022

Polypid Ltd Announces Completion of Enrollment in Phase 3 Shield I Trial of D-Plex for Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

PolyPid Ltd. Announces Executive Changes

PolyPid: Strong Pipeline, Close Catalysts

PolyPid Ltd. announced that it expects to receive $15 million in funding from Kreos Capital Management (UK) Limited

PolyPid Ltd., Annual General Meeting, May 03, 2022

Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

PolyPid Ltd. Announces 750Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 in Abdominal Surgery

PolyPid Ltd. Announces 750Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 in Abdominal Surgery

PolyPid Ltd. Announces CEO Changes

Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

PolyPid Ltd. Announces Positive FDA Type B Meeting Feedback for D-Plex Development Program

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid Ltd., Annual General Meeting, Apr 13, 2021

Polypid Ltd. Announces 100Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 for the Prevention of Post-Abdominal Surgery Incisional Infections

New 90-day high: US$12.75

PolyPid Ltd. to Report Q4, 2020 Results on Feb 10, 2021

PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program

PolyPid's oncoplex cancer program shows encouraging action in animal study

PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

New 90-day low: US$9.98

PolyPid Ltd. to Report Q3, 2020 Results on Nov 11, 2020